Synta Pharma Home



CLINICAL TRIALS

Clinical trials are a fundamental step in the development of new therapies for treating virtually every medical condition. At Synta Pharmaceuticals, our clinical research is focused on innovative therapeutic options that can extend or enhance the lives of patients in the areas of cancer and inflammatory diseases. All of the drug candidates currently in development at Synta are derived from our proprietary chemical compound library and reflect our commitment to truly original research.

Synta places a high priority on sharing information and results regarding our ongoing and completed clinical studies with the medical community. We have registered all of our active, company-sponsored clinical trials on the National Institutes of Health Web site www.clinicaltrials.gov. This information is available here on our site, as well.

No Synta drug candidates have been approved by the FDA or any other regulatory body for the treatment of diseases.

STA - 9090

STA-9090 is a novel, synthetic, injectable, small molecule Hsp90 inhibitor (inhibits heat shock protein 90 - Hsp90), a chaperone that regulates numerous proteins that drive proliferation in cancer cells, in particular kinases) with a novel chemical structure that is unrelated to the Hsp90 inhibitor geldanamycin or its family of related compounds, such as 17-AAG.

Phase 1 Solid Tumor Trials

Two trials are being conducted: one with a once-weekly dosing schedule, one with a twice-weekly dosing schedule. The primary objective of both studies is to identify maximum tolerated dose; secondary objectives are to characterize safety, tolerability, signs of biologic and clinical activity.

Click here to get more information on our once-weekly trial.

Click here to get more information on our twice-weekly trial.

Phase 1/2 Trials in Hematologic Malignancies

Two trials are being conducted: one with a once-weekly dosing schedule, one with a twice-weekly dosing schedule. The primary objective of both studies is to identify maximum tolerated dose; secondary objectives are to characterize safety, tolerability, signs of biologic and clinical activity.

Click here to get more information on our once-weekly trial.

Click here to get more information on our twice-weekly trial.

Phase 2 Trial in Non-Small Cell Lung Cancer

This trial is an open-label, multi-center, multi-cohort Phase 2 study designed to characterize the efficacy and safety of STA-9090 in patients with stage IIIB or IV non-small cell lung cancer, based on a once-weekly dosing schedule. Patients will be assessed for tumor response based on the RECIST criteria. Subjects tolerating STA-9090 may continue on treatment until disease progression. Click here for more information on this trial.

Phase 2 Trial in Gastrointestinal Stromal Tumors

This trial is an open-label, multi-center Phase 2 study designed to characterize the efficacy and safety of STA-9090 in patients with metastatic or unresectable GIST following failure of Gleevec® and Sutent®, based on a once-weekly intravenous dosing schedule. Patients will be assessed for clinical benefit rate per RECIST criteria. Click here for more information on this trial.

Phase 2 Trial in Colorectal Cancer

This is an open-label, investigator-sponsored Phase 2 clinical study being conducted in patients with advanced colon cancer or rectal cancer. Click here for more information on this trial.

Phase 2 Trial in Gastric Cancer

This is an open-label, investigator-sponsored Phase 2 clinical study being conducted in patients with advanced gastric, esophageal, or gastroesophageal cancers. Click here for more information on this trial.

[Top of page]

Contact Information:

Synta Pharmaceuticals
45 Hartwell Avenue
Phone 781-541-7125
Fax 781-274-1270

[Top of page]

ABOUT |  PIPELINE | CLINICAL TRIALS |  TECHNOLOGY |  INVESTORS  |  CAREERS

Copyright © 2010Synta Pharmaceuticals Corp. All rights reserved. Terms of Use